By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alkermes plc 

852 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-609-6000 Fax: n/a


About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes' website at

Key Executives
Richard F. Pops
Chairman and Chief Executive Officer

Shane Cooke

Kathryn L. Biberstein
Senior Vice President, General Counsel and Secretary, and Chief Compliance Officer

Mark Stejbach
Senior Vice President, Chief Commercial Officer

Georgianna Harris
Vice President, Regulatory Affairs

Madeline D. Coffin
Vice President, Human Resources

Elliot W. Ehrich, M.D.
Senior Vice President, Research and Development, and Chief Medical Officer

James M. Frates
Senior Vice President, Chief Financial Officer

Blair C. Jackson
Vice President, Business Development

Michael J. Landine
Senior Vice President, Corporate Development

Rebecca J. Peterson
Senior Vice President, Corporate Communications

Gordon G. Pugh
Senior Vice President, Chief Operating Officer and Chief Risk Officer

Peter Norman
Vice President, Government Affairs and Policy

Srdjan Stankovic
Senior Vice President, Clinical Development and Medical Affairs


Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000

Waltham, Massachusetts
852 Winter Street
Waltham, MA 02451
+1 781 609 6000

Athlone, Ireland
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000

Gainesville, Georgia
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100

Wilmington, Ohio
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642

Key Statistics

Ownership: Public

Web Site: Alkermes
Employees: 1,200
Symbol: ALKS

Drug Delivery

Company News
Alkermes (ALKS) Reports Second Quarter 2017 Financial Results 7/27/2017 6:26:35 AM
Alkermes (ALKS) To Host Conference Call To Discuss Second Quarter 2017 Financial Results 7/21/2017 7:51:39 AM
Alkermes (ALKS) Slips As Weight Gain Concerns Sully Late-Stage Schizophrenia Data 6/30/2017 5:46:44 AM
Alkermes (ALKS) Announces Initiation Of Study 217 For ALKS 5461 For Treatment Of Major Depressive Disorder 6/12/2017 7:56:24 AM
Alkermes (ALKS) Announces Initiation Of Phase III Study Of ALKS 3831 In Young Adult Patients 6/8/2017 6:51:22 AM
Alkermes (ALKS) Release: FDA Approves Two-Month ARISTADA For Treatment Of Schizophrenia 6/6/2017 7:08:01 AM
Alkermes (ALKS) Appoints Craig Hopkinson, M.D., As Chief Medical Officer, And Senior Vice President, Clinical Development And Medical Affairs 5/30/2017 6:02:54 AM
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming Society Of Biological Psychiatry Annual Meeting 5/12/2017 6:42:56 AM
Alkermes (ALKS) Announces Completion Of Patient Enrollment In Pivotal Antipsychotic Efficacy Study Of ALKS 3831 For Schizophrenia 5/1/2017 6:13:48 AM
Alkermes (ALKS) Reports First Quarter 2017 Financial Results 4/27/2017 5:32:02 AM